Advertisement

Topics

Celtaxsys, Inc. Company Profile

02:30 EST 17th November 2018 | BioPortfolio

Celtaxsys is privately-held start-up focused on discovery and development of therapeutics to treat inflammation. The Company has identified a portfolio of immunoregulators that redirect immune cell migration and activation. Initial product candidates can ameliorate acute and chronic inflammatory disorders of cutaneous, and other, barrier epithelia.


News Articles [15 Associated News Articles listed on BioPortfolio]

Celtaxsys cystic fibrosis drug reduces key symptom in mid-stage study

Privately held Celtaxsys Inc said on Thursday a mid-stage trial testing its experimental cystic fibrosis treatment was successful in reducing a key symptom of the genetic lung disease, but did not imp...

Celtaxsys to initiate late-stage study of cystic fibrosis drug

Celtaxsys plans to launch a late-stage trial late next year for drug candidate CTX-4430 in patients with cystic fibrosis.  -More- 

Celtaxsys’ Phase II Cystic Fibrosis Trial Fails, Despite Positive Spin

Atlanta-based Celtaxsys reported results from its Phase II EMPIRE-CF clinical trial of acebilustat for cystic fibrosis (CF), putting a positive spin on what looks to be a failed clinical trial.

Celtaxsys’ Cystic Fibrosis Drug Demonstrated Clinically Meaningful Improvements in Pulmonary Exacerbations in Phase 2 Trial

ATLANTA, Aug. 02, 2018 (GLOBE NEWSWIRE) — Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today...

Celtaxsys’ CF drug acebilustat reduces pulmonary exacerbations in phase 2 trial

Acebilustat is a small molecule inhibitor of Leukotriene A4 Hydrolase (LTA4H), the crucial enzyme in the production of the potent inflammatory mediator Leukotriene B4 (LTB4). The anti-inflammatory dru...

Celtaxsys planning Phase III program for CF candidate

Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients

-Acebilustat is the first novel anti-inflammatory molecule evidencing the potential to reduce frequency of pulmonary exacerbations and prolong time to first exacerbation in CF patients  --Celtaxsy...

Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Trial, Clinical Results Expected in July

ATLANTA, May 17, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today an...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Celtaxsys, Inc.

Celtaxsys is privately-held start-up focused on discovery and development of therapeutics to treat inflammation. The Company has identified a portfolio of immunoregulators that redirect immune cell mi...

More Information about "Celtaxsys, Inc." on BioPortfolio

We have published hundreds of Celtaxsys, Inc. news stories on BioPortfolio along with dozens of Celtaxsys, Inc. Clinical Trials and PubMed Articles about Celtaxsys, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celtaxsys, Inc. Companies in our database. You can also find out about relevant Celtaxsys, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record